Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
EJ Orlando, X Han, C Tribouley, PA Wood, RJ Leary… - Nature medicine, 2018 - nature.com
Nature medicine, 2018•nature.com
We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19–
relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast
majority of resistant tumor cells and are predicted to lead to a truncated protein with a
nonfunctional or absent transmembrane domain and consequently to a loss of surface
antigen. This irreversible loss of CD19 advocates for an alternative targeting or combination
CAR approach.
relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast
majority of resistant tumor cells and are predicted to lead to a truncated protein with a
nonfunctional or absent transmembrane domain and consequently to a loss of surface
antigen. This irreversible loss of CD19 advocates for an alternative targeting or combination
CAR approach.
Abstract
We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19– relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast majority of resistant tumor cells and are predicted to lead to a truncated protein with a nonfunctional or absent transmembrane domain and consequently to a loss of surface antigen. This irreversible loss of CD19 advocates for an alternative targeting or combination CAR approach.
nature.com